PRME
Prime Medicine, Inc.
3.90$
+11.4%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Prime Medicine, Inc. (PRME) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -41 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 19 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.3 | -2.5 | -4.9 | -6.4 | -9.6 | -13 | -51 | -20 | -30 | -31 | -42 | -41 | -39 | -44 | -68 | -45 | -26 | 16 | -49 | -41 | -35 | -37 | -43 | -41 | -156 | |
| – | 0.0 | 0.7 | 1.2 | 0.2 | 0.2 | 0.3 | 0.4 | 0.6 | 0.9 | 1.1 | 1.1 | 1.2 | 1.2 | 1.3 | 1.5 | 1.6 | 1.7 | 1.5 | 1.5 | 1.9 | 0.5 | 1.9 | 1.8 | 6.0 | |
| 0.2 | -0.3 | 0.2 | 0.1 | 0.3 | 1.1 | 1.1 | 1.3 | 1.4 | 2.6 | 1.7 | 3.6 | 4.2 | 4.4 | 5.2 | 8.1 | 6.8 | 5.9 | 5.7 | 6.3 | 13 | 4.5 | 4.6 | 4.9 | 27 | |
| – | – | – | -7.4 | – | 21 | 7.0 | 7.1 | 2.5 | 6.5 | 1.5 | 3.6 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.5 | 0.5 | 0.2 | 0.2 | -0.8 | 32 | -34 | 1.6 | -3.8 | 1.2 | -8.6 | -5.6 | 2.4 | 14 | -30 | 8.8 | 3.6 | 49 | -7.7 | 0.5 | 0.6 | 1.2 | -2.5 | -8.1 | -8.9 | |
| 0.0 | 0.3 | 1.0 | 0.9 | 1.8 | 0.4 | 1.7 | 4.8 | 4.8 | 4.8 | 2.0 | 2.0 | 2.9 | 1.8 | 2.3 | 1.9 | 1.3 | 1.8 | 2.4 | 1.6 | 0.2 | 0.3 | 0.2 | 0.0 | 0.8 | |
| – | -0.4 | -1.0 | -77 | -7.6 | 12 | 31 | -51 | -14 | -14 | -13 | 28 | -38 | 41 | -37 | 6.9 | 50 | 48 | -48 | 2.8 | -92 | 28 | 43 | 24 | 3.6 | |
| – | – | – | – | – | – | – | – | – | – | 0.1 | 0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 10.0 | 35 | 2.3 | 268 | 0.0 | -1.1 | -1.3 | -0.6 | -0.7 | 184 | 0.1 | 0.1 | 0.3 | 0.2 | 157 | 0.0 | 39 | 0.0 | 6.0 | 0.2 | 145 | 0.6 | 0.4 | 0.4 | 146 | |
| 8.6 | 37 | -3.5 | 184 | -17 | -2.1 | -21 | -72 | -44 | 140 | -54 | -13 | -77 | -2.4 | 53 | -39 | 63 | 64 | -91 | -38 | 18 | -8.4 | 1.1 | -17 | -6.4 | |
| -1.3 | -2.8 | -5.9 | -7.3 | -11 | -14 | -52 | -25 | -35 | -36 | -44 | -43 | -42 | -46 | -70 | -47 | -27 | 14 | -51 | -43 | -35 | -38 | -43 | -41 | -157 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.